Exploiting Emerging Supramolecules as In Vivo Sequestrants to Induce Drug Reversal

Estado	Finalizado
Fecha de inicio/Fecha fin	3/5/24 → 12/31/24

Financiación

Reversal Therapeutics Incorporated: 34.187,00 US$

Alpha2 Noradrenergic Antagonist as a Fentanyl Counter Measure
Bardo, M. (PI), Prisinzano, T. (PI) & Alilain, W. (CoI)
University of Kentucky Neuroscience Research Priority Area
1/1/23 → 12/31/23
Proyecto: Research project